Embed Size (px)
DESCRIPTION
Rising Drug Costs & Lack of New Treatments As the U.S. deals with spiraling drug costs and an urgent need for new treatments, the Myelin Repair Foundation has pioneered a holistic approach to multiple sclerosis drug development that bridges the gap between the promising discoveries made in academic laboratories and big pharmaceutical drug research and development. The approach shows early promise in cutting development costs and shaving years off of the time it takes to develop a drug from basic science to patient therapy. The Myelin Repair Foundation’s approach will not only benefit the millions living with MS but also provides a new source of high-quality drug targets for the dwindling biopharma pipelines. Investing in Innovation The Ewing Marion Kauffman Foundation, Pioneer Portfolio of the Robert Wood Johnson Foundation, and the Scott Cook & Signe Ostby Foundation are investing in MRF’s unique approach, its potential to accelerate the drug development process. Online Webinar: March 25, 2010 All three organizations held a webinar on March 25, 2010 session to discuss why they support the MRF model and why attention should be paid to this new research paradigm. Contact [email protected] with questions or media requests.
Citation preview
Developing Cures with Less Time & Capital:A New Research Model to
Accelerate Drug Development
March 25, 2010
Margaret Anderson
Executive Director, FasterCures
Catalyzing efforts across sectors to improve the effectiveness and efficiency of the medical research enterprise
Committed to analyzing barriers to progress and overcoming them through action
Agenda
Overview of Research Development Process
Panel Discussion
Open Questions
Participants
• Scott Johnson, President and Founder, Myelin Repair Foundation
• Lesa Mitchell, Vice President, Advancing Innovation, Kauffman Foundation
• Nancy Barrand, Special Adviser for Program Development, Robert Wood Johnson Foundation
• Scott Cook, Co-founder of the Scott Cook & Signe OstbyFoundation and co-founder of Intuit Inc.
• Host: Margaret Anderson, Executive Director of FasterCures
Scott Johnson
Founder and President, Myelin Repair Foundation
Waiting for a cure for MS since 1976
Leading the way toward faster development of new treatments and cures for ALL diseases
Crisis in Health Care
Effective new treatments for difficult diseases are far too slow in reaching patients who can’t afford to wait.
The economic impact in the U.S. of these untreated diseases is estimated at $1.3 trillion annually.
Shrinking pharma pipeline threatens industry.
Shrinking venture capital funding for biotech startups.
Increasing R&D Spend, but Flat Results
1. IMDs (Incrementally Modified Drugs) are new derivatives, formulations and combinations2. NME (New Molecular Entities) include both chemical and biological therapeutic agents, excludes contrast agents and diagnosticsSource: FDA, PhRMA 2005 Yearbook
…but NME approvals relatively flat
0
70
140
’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02 ’03 ’04 ’05
No. of approvals
NMEs
INDs
R&D spending has grown steadily…
0
15
30
45
’91 ’92 ’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02 ’03 ’04 ’05
($B)
CAGR
11.3%
CAGR
10.5%
Domestic R&D
R&D abroad
Evolution of the Medical Research Enterprise
1940 2010Paradigm
shift
Holistic Approach Manages to Milestones:
Accelerating Basic Science
Holistic Approach Manages to Milestones:
Building a Network of CROs
Holistic Approach Manages to Milestones:
Building Partnerships with Biopharma
Holistic Approach Manages to Milestones
MRF ARC Model
Shifting the Paradigm:
Rapid Results at Far Lower Cost
Published > 75 peer-reviewed scientific articles.
Established first partnership with pharmaceutical company to review and validate academic discoveries.
• Demonstrated that myelin can be repaired in animal models of
MS.
• Identified 144 discoveries that have the potential to repair
myelin; prioritized top 20 discoveries to develop further.
• Developed 24 new research tools.
• Created significant intellectual property; 20 patentable
inventions
Panelists
• Scott Johnson, President and Founder, Myelin Repair Foundation
• Lesa Mitchell, Vice President, Advancing Innovation, Kauffman Foundation
• Nancy Barrand, Special Adviser for Program Development, Robert Wood Johnson Foundation
• Scott Cook, Co-founder of the Scott Cook & Signe Ostby Foundation and co-founder of Intuit Inc.
Nancy Barrand
Special Adviser for Program Development, Robert Wood Johnson Foundation
Works to ensure health coverage for all Americans, improve the social factors that shape health for vulnerable populations, and support innovative ideas that can transform the future of health and health care
Wants to make the research enterprise work faster and more openly to accelerate treatment discoveries and cures
Lesa Mitchell
Vice President of Advancing Innovation, Ewing Marion Kauffman Foundation
20 years experience in biotech and pharmaceutical entrepreneurship
Committed to improving pathways that shepherd research from universities and labs through commercialization
Scott Cook
Founder & Chairman of the Executive Committee - Intuit
Board Member – Procter & Gamble, eBay, Intuit
Catalyst of paradigm change in health care, education, and Internet access for the developing world
Panelists
• Scott Johnson, President and Founder, Myelin Repair Foundation
• Lesa Mitchell, Vice President, Advancing Innovation, Kauffman Foundation
• Nancy Barrand, Special Adviser for Program Development, Robert Wood Johnson Foundation
• Scott Cook, Co-founder of the Scott Cook & Signe Ostby Foundation and co-founder of Intuit Inc.
• Host: Margaret Anderson, Executive Director of FasterCures
For More Information
Carol Menaker
408-871-2410
Myelin Repair Foundation
http://myelinrepair.org
http://wherearethecures.org
Kelly Rohrs
212-819-4852
Edelman
